162 related articles for article (PubMed ID: 15553311)
1. Dyslipidemia in patients with angiographically confirmed coronary artery disease--an opportunity for improvement.
Khanal S; Obeidat O; Lu M; Douthat L; Hudson MP; Greenbaum AB; Kugelmass A; Weaver WD
Clin Cardiol; 2004 Oct; 27(10):577-80. PubMed ID: 15553311
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering medications: what the new guidelines and data mean to women.
Schwartz JB
J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
[No Abstract] [Full Text] [Related]
3. Getting more people on statins.
Roberts WC
Am J Cardiol; 2002 Sep; 90(6):683-5. PubMed ID: 12231110
[No Abstract] [Full Text] [Related]
4. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
5. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease.
Kauffman AB; Olson KL; Youngblood ML; Zadvorny EB; Delate T; Merenich JA;
J Clin Lipidol; 2010; 4(3):173-80. PubMed ID: 21122649
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
Ryan MJ; Gibson J; Simmons P; Stanek E
Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
[TBL] [Abstract][Full Text] [Related]
7. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure.
Sueta CA; Massing MW; Chowdhury M; Biggs DP; Simpson RJ
J Card Fail; 2003 Feb; 9(1):36-41. PubMed ID: 12612871
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
9. Achieving optimal lipid goals in patients with coronary artery disease.
Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
[TBL] [Abstract][Full Text] [Related]
10. Normocholesterolaemic dysslipidaemia: is there a role for fibrates?
Hamilton-Craig I
Med J Aust; 2001 Jun; 174(11):610; author reply 611. PubMed ID: 11453341
[No Abstract] [Full Text] [Related]
11. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
[TBL] [Abstract][Full Text] [Related]
12. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
13. Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults.
Björnsson E; Thorleifsson G; Helgadóttir A; Guðnason T; Guðbjartsson T; Andersen K; Grétarsdóttir S; Ólafsson Í; Tragante V; Ólafsson ÓH; Jónsdóttir B; Eyjólfsson GI; Sigurðardóttir Ó; Thorgeirsson G; Guðbjartsson DF; Thorsteinsdóttir U; Hólm H; Stefánsson K
JAMA Cardiol; 2020 Jan; 5(1):13-20. PubMed ID: 31746962
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin on coronary plaque volume.
Ishikawa K; Tani S; Watanabe I; Matsumoto M; Furukawa K; Nomoto K; Nomoto K; Kushiro T; Nagao K; Kanmatsuse K
Am J Cardiol; 2003 Oct; 92(8):975-7. PubMed ID: 14556877
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
[TBL] [Abstract][Full Text] [Related]
19. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease.
Karalis DG
Mayo Clin Proc; 2009 Apr; 84(4):345-52. PubMed ID: 19339653
[TBL] [Abstract][Full Text] [Related]
20. Lipid disorders: justification of methods and goals of treatment.
Braunstein JB; Cheng A; Cohn G; Aggarwal M; Nass CM; Blumenthal RS
Chest; 2001 Sep; 120(3):979-88. PubMed ID: 11555537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
